---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039793"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:40:46.302957+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CytomX Q2 revenue $24.7M (up 91% YoY); cash runway into H2 2025 after $30M financing

## Summary
- Cash, equivalents & investments $180.9M at June 30, 2023; $30M gross financing from BVF closed July 2023.
- Revenue $24.7M (vs $12.9M Q2 2022) driven by BMS collaboration; R&D expenses fell to $20.7M.
- CX-904 (EGFRxCD3) Phase 1 dose escalation data anticipated first half of 2024; backfill cohorts by end 2023.
- IND filings for wholly-owned CX-2051 (EpCAM ADC) and CX-801 (IFNa2b) expected Q4 2023.
- Appointed Dr. Wayne Chu as CMO; promoted Dawn Benson to SVP Quality and Product Manufacturing.

## SEC filing metadata
- accession: 0000950170-23-039793
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000095017023039793/0000950170-23-039793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000095017023039793/ctmx-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039793
- JSON: https://secwatch.observer/filing/0000950170-23-039793.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039793.txt

## Key facts
- Earnings Releases
  CytomX Therapeutics, Inc. reported financial results for second quarter 2023.
  - Period: second quarter 2023
  - Result: reported results
  source text: On August 8, 2023, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results as of and for the three and six months ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000095017023039793/0000950170-23-039793-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.